Search

Résumé: Objectifs. Résumer la littérature relative aux rôles du pharmacien en dermatologie-allergologie, présenter un profil succinct de ces deux secteurs et développer une offre de soins pharmaceutiques cohérente en dermatologie-allergologie au Centre hospitalier universitaire (CHU) Sainte-Justine. Méthodes. Il s'agit d'une étude descriptive constituée d'une revue de littérature des articles portant sur le rôle du pharmacien en dermatologie-allergologie, d'une description sommaire des secteurs de la dermatologie et de l'allergologie, ainsi que de la mise à jour de l'offre de soins pharmaceutiques dans ces secteurs. Résultats. Un total de 35 articles (16 en dermatologie et 19 en allergologie) ont été inclus dans la revue de littérature. La majorité de ces articles était de faible qualité et décrivait les activités pharmaceutiques sans en mesurer l'impact. Les activités pharmaceutiques principalement rapportées par la littérature étaient la réalisation de conseils aux patients (articles de dermatologie) et la documentation des interventions effectuées (articles d'allergologie). En 2017-2018, les secteurs de la dermatologie et de l'allergologie ont effectué environ 14 000 et 5 000 consultations médicales de façon respective. L'offre de soins pharmaceutiques a été mise à jour en fonction de 21 activités pharmaceutiques, permettant d'identifier la pertinence d'un pharmacien répondant en dermatologie-allergologie. Conclusion. Il existe peu de données sur les rôles et les retombées de l'activité pharmaceutique en dermatologie-allergologie. Cet article présente une démarche originale incluant une revue de littérature (35 articles), un profil succinct des secteurs et une réflexion entourant les activités pharmaceutiques d'un pharmacien répondant en dermatologie-allergologie au sein d'un centre hospitalier universitaire mère-enfant. Objectives. Summarize the literature on the pharmacist's role in dermatology-allergology, present a brief description of these two sectors and develop a pharmaceutical care offer in dermatology-allergology in a mother-child teaching hospital center. Methods. This article is a descriptive study consisting of a literature review on the pharmacist's role in dermatology-allergology, a brief description of the dermatology and allergology sectors and an optimization of the pharmaceutical care in these sectors. Results. A total of 35 articles (16 in dermatology and 19 in allergology) were included in the literature review. The majority of these articles were of poor quality and described the pharmaceutical activities without measuring their impact. The pharmaceutical activities mainly reported in the literature were the advices to patients (dermatology articles) and the documentation of the pharmaceutical interventions (allergy articles). In 2017-2018, the dermatology and allergology sectors performed approximately 14,000 and 5,000 medical consultations respectively. The pharmaceutical care offer has been updated, allowing us to identify the relevance of a responding pharmacist in dermatology-allergology. Conclusion. There is few data on the roles and outcomes of the dermatology-allergology pharmaceutical activities. This article presents an original approach including a literature review (35 articles), a brief profile of the sectors and a reflection on the pharmaceutical activities of a dermatology-allergology pharmacist in a mother-child teaching hospital center. [ABSTRACT FROM AUTHOR]

Background: Oral psychostimulant (PS) drugs, the pharmacologic treatment of choice for attention-deficit/hyperactivity disorder (ADHD), have been associated with diseases of abnormal sensitivity to cold (DASC) such as Raynaud phenomenon and acrocyanosis. Objectives: In a cohort of pediatric patients with DASC, we sought to identify prevalence and clinical features of patients on PS drugs. Methods: A 6-year retrospective chart review (2005-2011) of Ste-Justine University Hospital Center DASC patients with and without exposure to PS drugs was performed. Clinical data were analyzed with descriptive statistical methods. Results: Of 43 patients with DASC, 11 (25%) were exposed to PS drugs. In this group males were overrepresented, there was no evidence of collagen vascular diseases, serologic findings were not significant and the mean duration of PS intake was of 2.5 years. DASC age of onset was similar in both exposed and nonexposed patients. The incidence of more than one DASC type was greater in teenager patients with a positive family history of autoimmune and/or collagen vascular diseases. Limitations: This study is limited by its small population size, short follow-up period and its retrospective nature. Conclusion: Physicians should be aware of PS drugs as possible triggers for DASC. [ABSTRACT FROM AUTHOR]

Competing Interests: Competing interests: None declared.

Competing Interests: Intérêts concurrents: Jérôme Coulombe signale avoir reçu des honoraires personnels de Galderma, Leo Pharma, Novartis et Pfizer, indépendamment des travaux soumis. Aucun autre intérêt concurrent n’a été déclaré.

Background: Oral psychostimulant (PS) drugs, the pharmacologic treatment of choice for attention-deficit/hyperactivity disorder (ADHD), have been associated with diseases of abnormal sensitivity to cold (DASC) such as Raynaud phenomenon and acrocyanosis., Objectives: In a cohort of pediatric patients with DASC, we sought to identify prevalence and clinical features of patients on PS drugs., Methods: A 6-year retrospective chart review (2005-2011) of Ste-Justine University Hospital Center DASC patients with and without exposure to PS drugs was performed. Clinical data were analyzed with descriptive statistical methods., Results: Of 43 patients with DASC, 11 (25%) were exposed to PS drugs. In this group males were overrepresented, there was no evidence of collagen vascular diseases, serologic findings were not significant and the mean duration of PS intake was of 2.5 years. DASC age of onset was similar in both exposed and nonexposed patients. The incidence of more than one DASC type was greater in teenager patients with a positive family history of autoimmune and/or collagen vascular diseases., Limitations: This study is limited by its small population size, short follow-up period and its retrospective nature., Conclusion: Physicians should be aware of PS drugs as possible triggers for DASC.